Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TW11681 and TW10722
- Development stage
- Unknown
- Lead developer
- University of Bergen
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
TW11681 and TW10722 are live bacterial challenge strains of enterotoxigenic *Escherichia coli* (ETEC) developed by the University of Bergen for use in controlled human infection models (CHIMs). These strains are specifically selected to produce heat-stable enterotoxin (ST) but not heat-labile toxin (LT), making them suitable for evaluating the efficacy of ST-based vaccine candidates. TW11681 (serotype O19:H45) expresses colonization factors CFA/I and CS21, while TW10722 (serotype O115:H5) expresses CS5 and CS6. In clinical studies, these strains are administered orally to healthy volunteers to induce experimental diarrhea, establishing a standardized challenge model for vaccine testing. TW10722 has been identified as particularly effective, achieving high attack rates at specific doses.
- Other names
- ETEC challenge strainsST-only ETEC strains
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on TW11681 and TW10722.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TW11681 and TW10722.